...
首页> 外文期刊>Journal of Agricultural and Food Chemistry >Gastro-Resistant Insulin Receptor-Binding Peptide from Momordica charantia Improved the Glucose Tolerance in Streptozotocin-Induced Diabetic Mice via Insulin Receptor Signaling Pathway
【24h】

Gastro-Resistant Insulin Receptor-Binding Peptide from Momordica charantia Improved the Glucose Tolerance in Streptozotocin-Induced Diabetic Mice via Insulin Receptor Signaling Pathway

机译:来自MOMORDICA CHARANTIA的胃抗性胰岛素受体结合肽通过胰岛素受体信号通路改善了链脲佐菌素诱导的糖尿病小鼠的葡萄糖耐量

获取原文
获取原文并翻译 | 示例
           

摘要

Momordica charantia is a commonly used food and has been used for the management of diabetes. Our previous study has identified an insulin receptor (IR)-binding protein (mcIRBP) from Momordica charantia. Here we identified the gastroresistant hypoglycemic bioactive peptides from protease-digested mcIRBP. By in vitro digestion and IR kinase activity assay, we found that a 9-amino-acid-residue peptide, mcIRBP-9, was a gastro-resistant peptide that enhanced IR kinase activities. mcIRBP-9 activated IR signaling transduction pathway, which resulted in the phosphorylation of IR, the translocation of glucose transporter 4, and the uptake of glucose in cells. Intraperitoneal and oral administration of mcIRBP-9 stimulated the glucose clearance by 30.91 +/- 0.39% and 32.09 +/- 0.38%, respectively, in streptozotocin-induced diabetic mice. Moreover, a pilot study showed that daily ingestion of mcIRBP-9 for 30 days decreased the fasting blood glucose levels and glycated hemoglobin (HbA1c) levels by 23.62 +/- 6.14% and 24.06 +/- 1.53%, respectively. In conclusion, mcIRBP-9 is a unique gastro-resistant bioactive peptide generated after the digestion of mcIRBP. Furthermore, oral administration of mcIRBP-9 improves both the glucose tolerance and the HbA1c levels in diabetic mice via targeting IR signaling transduction pathway.
机译:Momordica Charantia是一种常用的食物,已被用于糖尿病的管理。我们以前的研究已经确定了来自Momordica Charantia的胰岛素受体(IR) - 粘连蛋白(Mcirbp)。在这里,我们鉴定了来自蛋白酶消化的MciRBP的胃抗蚀剂降血糖生物活性肽。通过体外消化和IR激酶活性测定,发现9-氨基酸 - 残基肽Mcirbp-9是增强IR激酶活性的耐胃抗性肽。 McirBP-9活化的IR信号转导通路,导致IR的磷酸化,葡萄糖转运蛋白4的易位和细胞中葡萄糖的摄取。 MciRBP-9的腹膜内和口服给药分别在链脲佐菌素诱导的糖尿病小鼠中刺激葡萄糖清除30.91 +/- 0.39%和32.09 +/- 0.38%。此外,试验研究表明,每日摄入McirBP-9 30天,分别将空腹血糖水平和糖化血红蛋白(HBA1C)水平降低23.62 +/- 6.14%和24.06 +/- 1.53%。总之,Mcirbp-9是在消化Mcirbp后产生的独特的胃抗性生物活性肽。此外,通过靶向IR信号转导通路,口服Mcirbp-9的口服给予糖尿病小鼠中的葡萄糖耐量和HBA1C水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号